UHS Clinical Trials

Nymox BPH Study – Phase 3, double blind, multicenter, prospective, randomized, placebo-controlled clinical evaluation of NX-1207 for the treatment of BPH 

Principal Investigator:                        Guy Bernstein, M.D.

Endo Pharmaceuticals Bladder Cancer Study – Phase 3,  multicenter, randomized, open-label evaluation of  EN3348 (MCC) as compared with Mitomycin C in the intravesical treatment of patients with BCG recurrent or refractory non-muscleinvasive bladder cancer

Principal Investigator:                        Guy Bernstein, M.D.

GP Pharm Prostate Cancer Study – Efficacy and safety of a new leuoprolide acetate 22.5 mg depot formulation in the treatment of prostate cancer.

Principal Investigator:                        Guy Bernstein, M.D.

Testosterone Deficiency in Men with Inflammatory Bowel Disorder – A prelminary investigation into testosterone levels and symptoms of low testosterone in men with IBD

Principal Investigator:                        GuyBernstein, M.D.

Auxilium Pharmaceuticals Peyronie's Disease Study – Phase 3, double-blind, randomized, placebo-controlled study of Xiaflex in men with Peyronie's Disease

Principal Investigator:                        Guy Bernstein, M.D.

Dendreon P-11 (Protect) Study – Provenge immunotherapy trial for rising PSA after prostate cancer surgery with no evidence of metastasis.

Principal Investigator:                        Guy Bernstein, M.D.

Spectrum Pharmaceuticals Eoquin Study  – Multi-centered, randomized, placebo-controlled, double blind Phase 3 trial of Single-Dose Intravesical Eoquin as a surgical adjuvant following TURBT

Principal Investigator:                        Guy Bernstein, M.D.

Predictive Biosciences Study  - Hematuria evaluation study

Principal Investigator:                        Guy Bernstein, M.D.